In recent decades, the European Union (EU) has increased its overall effort in cancer research, as well as its support through funding mechanisms that include, among others, public-private partnerships aimed at strengthening the innovative translation of research findings into clinical application.
In this context, the TRANSCAN network -established in 2011- has been pivotal in this effort. Over the years, the network has proven to be an excellent model of pan-European transnational cooperation by supporting high-quality translational cancer research through highly competitive and successful joint calls for proposals since its creation, and allowing an efficient allocation of dedicated national/regional resources, public and private, with a total real investment of about €126M. These resources, comprising core EU funding of approximately €18M, have been allocated from 2011 to 2023 to fund 113 research projects, involving 557 principal investigators from 19 different countries.
Building up on the well-established cooperation amongst the participating funding organisations, through the harmonisation of funding mechanisms and programmes, this new TRANSCAN-3 action aims at becoming a catalyst for a sustainable model of funding of cancer research in Europe, with an approach driven by what is beneficial to cancer patients and to society as a whole.
In this section of the website, you will find information on the outputs of the TRANSCAN-3 initivative and its predecesors programs, including but not limited to:
- a collection of funded projects;
- success stories of research projects that have had exceptional results in terms of impact; and
- statistics and data on granted projects, broken down by call year, countries, funders, gender and type of cancer, etc.